Pietro Sormanni

Nov 4, 2024 | nature.com | Laura Spector |Wei Qing Wang |Pietro Sormanni |Monica L. Fernández-Quintero |Andrew Ward |Charlotte M. Deane | +7 more

Science is frequently subject to the Gartner hype cycle1: emergent technologies spark intense initial enthusiasm with the recruitment of dedicated scientists. As limitations are recognized, disillusionment often sets in; some scientists turn away, disappointed in the inability of the new technology to deliver on initial promise, while others persevere and further develop the technology.

Apr 16, 2024 | nature.com | Robert Horne |Ewa Andrzejewska |Pietro Sormanni |Byron Caughey

AbstractMachine learning methods hold the promise to reduce the costs and the failure rates of conventional drug discovery pipelines. This issue is especially pressing for neurodegenerative diseases, where the development of disease-modifying drugs has been particularly challenging. To address this problem, we describe here a machine learning approach to identify small molecule inhibitors of α-synuclein aggregation, a process implicated in Parkinson’s disease and other synucleinopathies.